Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas

Inclusion Criteria:

• Pathologically confirmed GBM (including all histologic variants) at first diagnosiswith radiographic evidence of recurrent disease after treatment with radiotherapy andtemozolomide;
• 18 years of age or older
• Participants enrolling in the medical arm (Arms B, C and D) must be on a stable ordecreasing dose of corticosteroids (or none) for at least 5 days prior to the baselineMRI;
• Measurable disease (according to RANO guidelines)
• Surgical arm (Arm A) must be predicted pre-operatively to have sufficiently sizedtumor to be resected and provide tissue samples for exploratory assessments.

Exclusion Criteria:

• Markedly decreased visual acuity if attributed to other causes than GBM.
• Known active hepatitis A, B, or C
• Participants with coagulation problems and medically significant bleeding in the monthprior to start of treatment (e.g., peptic ulcer, epistaxis, spontaneous bleeding).Prior history of DVT or PE is not exclusionary.
• Participants must not have significantly diseased or obstructed gastrointestinaltract, malabsorption, uncontrolled vomiting or diarrhea, or inability to swallow oralmedications.
• Prior treatment with bevacizumab or other direct VEGF/ VEGFR inhibitors. For anyquestion of the definition of a direct VEGF/VEGFR inhibitor, consult Sponsor.
• Arms C and D only: body surface area < 1.2 m².
• < 24 days from prior temozolomide, < 6 weeks from nitrosourea, < 4 weeks from otherchemotherapy or investigational agents prior to start of treatment within study.